Selective induction of apoptosis in multidrug resistant HL60R cells by the thiazolobenzoimidazole derivative 1-(2,6-difluorophenyl)-1H,3H-thiazolo [3,4-a] benzimidazole (TBZ)

European Journal of Cancer

Volumn 34, Issue 11, 1998, Pages 1756-1763

  Grimaudo, S ^a   Tolomeo, M ^b   Chimirri, A ^c   Zappala, M ^c   Gancitano, R A ^b   D'Alessandro, N ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

Apoptosis; HL60 leukaemia; Multidrug resistance; Thiazolobenzimidazole

Indexed keywords

1 (2,6 DIFLUOROPHENYL) 1H,3H THIAZOLO[3,4 A]BENZIMIDAZOLE; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; DAUNORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; MITOXANTRONE; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN HL 60; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKEMIA CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTI-HIV AGENTS; APOPTOSIS; BENZIMIDAZOLES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; HL-60 CELLS; HUMANS; P-GLYCOPROTEIN; PROTO-ONCOGENE PROTEINS C-BCL-2; THIAZOLES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032190484     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00141-5     Document Type: Article

References (35)

1. 1. Rothenberg M, Ling V. Multidrug resistance: molecular biology and clinical relevance. J Natl Cancer Inst 1989, 81, 907-910.
2. 2. Dietel M, Albrechts C. Second international symposium on cytostatic drug resistance. Cancer Res 1993, 53, 2683-2688.
3. 3. Gottesman MM. How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal foundation award lecture. Cancer Res 1993, 53, 747-754.
4. 4. Martin SJ, Green DR. Apoptosis and cancer: the failure of controls on cell death and cell survival. Crit Rev Oncol Hematol 1995, 18, 137-153.
5. 5. Boobis AR, Fawthrop DJ, Davies DS. Mechanisms of cell death. Trend Pharm Sci 1989, 10, 275-280.
6. 6. Kerr MR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972, 26, 239-257.
7. 7. Williams GT. Programmed cell death: apoptosis and oncogenesis. Cell 1991, 65, 1097-1098.
8. 8. Williams GT, Smith CA. Molecular regulation of apoptosis: genetic controls on cell death. Cell 1993, 74, 777-779.
9. 9. Carson DA, Ribeiro JM. Apoptosis and disease. Lancet 1993, 341, 1251-1254.
10. 10. Lennon SV, Martin SJ, Cotter TG. Dose-dependent induction of apoptosis in human tumor cell lines by widely diverging stimuli. Cell Prolif 1991, 24, 203-214.
11. 11. Collins RJ, Harmon BV, Souvlis T, Pope JH, Kerr JFR. Effects of cycloheximide on B-chronic lymphocytic leukaemic and normal lymphocytes in vitro: induction of apoptosis. Br J Cancer 1991, 64, 518-522.
12. 12. Walker PR, Smith C, Youdale T, Leblanc J, Whitfield JF, Sikorska M. Topoisomerase II-reactive drugs induce apoptosis in thymocytes. Cancer Res 1991, 51, 1078-1085.
13. 13. Del Bino G, Darzynkiewicz Z. Camptothecin, teniposide, or 4′-(9-Acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin induces degradation of nuclear DNA in the S phase of HL-60 cells. Cancer Res 1991, 51, 1165-1169.
14. 14. Kapuscinski J, Darzynkiewicz Z. Relationship between the pharmacological activity of antitumor drugs ametantrone and mitoxantrone (novantrone) and their ability to condense nucleic acids. Proc Natl Acad Sci USA 1986, 83, 6302-6306.
15. 15. Rotter V, Foord O, Navot N. In search of the functions of normal p53 protein. Trend Cell Biol 1993, 3, 46-49.
16. 16. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993, 362, 847-849.
17. 17. Lowe SW, Ruley BE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993, 74, 951-967.
18. 18. Kinzler KW, Bogelstein B. Clinical implications of basic research: cancer therapy meets p53. New Eng J Med 1994, 331, 49-50.
19. 19. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990, 348, 334-338.
20. 20. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993, 81, 151-157.
21. 21. Chimirri A, Grasso S, Monforte AM, Monforte P, Zappala' M. Anti-HIV agents II: synthesis and in vitro anti-HIV activity of novel 1H,3H-thiazolo[3,4-a]benzimidazoles. Il Farmaco 1991, 46, 925-933.
22. 22. Hizi A, Tal R, Shaharabany M, et al. Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors. Antimicrob Agents Chemother 1993, 37, 1037-1042.
23. 23. Tinwalla AY, Hoesterey BL, Xiang T, Anderson BD. Solubilization of thiazolobenzimidazole using a combination of pH adjustment and complexation with 2-hydroxypropyl-β-cyclodextrin. Pharm Res 1993, 10, 1136-1143.
24. 24. El Dareer SM, Tillery KF, Rose LM, et al. Metabolism and disposition of a thiazolobenzimidazole active against human immunodeficiency virus-1. Drug Metab Disp 1993, 21, 231-235.
25. 25. Buckheit RW, Hollingshead MG, Germany-Decker J, et al. Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor. Antiviral Res 1993, 21, 247-265.
26. 26. Artico M. Non nucleoside anti-HIV reverse transcriptase inhibitors (NNRTIs); a chemical survey from lead compounds to select drugs for clinical trials. Il Farmaco 1996, 51, 305-331.
27. 27. Chimirri A, Grasso S. Molica C, et al. Structural features and anti-HIV activity of the isomers of 1-(2′,6′-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Antiviral Chem Chemother 1997, 8, 83-90.
28. 28. Wolf D, Rotter V. Major deletions in the gene encoding the p53 expression in HL60 cells. Proc Natl Acad Sci USA 1985, 82, 790-794.
29. 29. Duke RC, Cohen JJ. Morphological and biochemical assays of apoptosis. In JE Coligan, AM Kruisbeak, eds. Current Protocols in Immunology. New York, John Wiley & Sons, 1992, 3.17.1-3.17.16.
30. 30. Kaufmann SH. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin and other cytotoxic anticancer drugs: a cautionary note. Cancer Res 1989, 49, 5870-5878.
31. 31. Bertrand R, Kerrigan D, Sarang M, Pommier Y. Cell death induced by topoisomerase inhibitors. Role of calcium in mammalian cells. Biochem Pharmacol 1991, 42, 77-85.
32. 32. Harker GW, Slade DL, Parr RL, Feldhoff PW, Sullivan DM, Hoguin MH. Alterations in the topoisomerase IIalpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res 1995, 55, 1707-1716.
33. 33. Flandina C, Flugy A, Borsellino N, D'Alessandro N. Development and partial characterization of a human T-lymphoblastic leukemic (CCRF-CEM) cell line resistant to etoposide. Analysis of possible circumventing approaches. J. Chemother 1996, 8,465-471.
34. 34. Del Bufalo D, Biroccio A, Soddu S, et al. Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene. J Clin Invest 1996, 98, 1165-1173.
35. 35. Lyon RC, Cohen JS, Faustino PJ, Megninand F, Myers CE. Glucose metabolism in drug-sensitive and drug-resistant human breast cancer cells monitored by magnetic resonance spectroscopy. Cancer Res 1988, 48, 876-877.